A comprehensive view of non-vaccine biologics. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

California Institute for Regenerative Medicine sets up support program to help patients participate in clinical trials, with an emphasis on helping underserved populations; program expected to cost between US$300,000 – US$500,000 annually

Citius Pharmaceuticals partnering with University of Pittsburg, University of Minnesota in I/ONTAK clinical studies; I/ONTAK is recombinant fusion protein that combines interleukin-2 receptor binding domain with diphtheria toxin fragments

Global drug delivery system market projected to reach US$363.8B by 2030 with 6.1% CAGR growth from 2022 to 2030; growth driven by rising demand for biosimilars, vaccines, biologics, novel drug delivery systems

Cell therapy developed at Cedars-Sinai delays disease progression in Duchenne muscular dystrophy patients who have few treatment options; treatment uses cardiosphere heart muscle cells to improve heart, skeletal muscle function, blunt inflammation

BioMarin Pharmaceutical resubmits application to FDA for approval of injectable gene therapy valoctocogene roxaparvovec to treat severe hemophilia; if approved, the drug would be first commercially-available gene therapy in US to treat the condition

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count